Author

Eiman Elwakeel

Broad InstituteORCID 0000-0002-0219-9653Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Assay:CRISPR screen· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

Alan G. Zhang· 1 shared Andrew J. AguirreiD· 1 shared Arianny AcostaiD· 1 shared Arina AladyshevaiD· 1 shared Ashraf MohamediD· 1 shared Aurelia Dingley· 1 shared Bernard R. BrooksiD· 1 shared Changfei Luan· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alan G. Zhang

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 25, 2026

Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer

Richard Y. Ebright, Yao He, Alan G. Zhang…·William R. Sellers

The paper identifies combinatorial KRAS/FGFR dependence in pancreatic cancer through genetic interaction mapping and shows that combined inhibition overcomes resistance.

DOI 10.64898/2026.09.24.754062

humanCRISPR screen

𝕏 PostBluesky

Cancer BiologyACS OmegaPeer-reviewedMay 22, 2026

Machine Learning-Driven Drug Repurposing for KRAS G12C and KRAS G12D Inhibition

Gianluca Fuschi, J Germain, David Bebensee…·Muhamed Amin

This study uses machine learning to screen FDA-approved compounds for KRAS G12C and G12D inhibition, identifying potential drug candidates for further experimental validation.

1 citation

machine learning (classical)drug response / drug discovery

𝕏 PostBluesky